Drug intelligence / Profile preview

EOP2

Development stage: Preclinical
Lead developer: The Christie
Modality: Small Molecules
Administration: Topical

Overview

EOP2 is a second-generation essential oil pessary developed to treat urogenital atrophy (UA) in breast cancer survivors undergoing endocrine therapy. It is formulated with a cocoa butter base and contains a combination of three plant extracts/essential oils: Lavandula angustifolia, Chamaemelum nobile, and Calendula officinalis CO2 extract. This formulation was specifically designed to be minimally estrogenic, differentiating it from its predecessor (EOP1), which contained components with significant estrogenic activity. EOP2 aims to alleviate UA symptoms through the antibacterial, antifungal, and anti-inflammatory properties of its essential oil components, without the potential negative impact on breast cancer outcomes that could arise from systemic estrogen absorption.

Other names: second-generation EOP

Beyond the preview

Go deeper on EOP2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EOP2.

Explore the full profile